Although leptin is known to increase sympathetic nerve activity (SNA), we tested the hypothesis that leptin also enhances baroreflex control of SNA and heart rate (HR). Using α-chloralose anesthetized male rats, mean arterial pressure (MAP), HR, lumbar SNA (LSNA), splanchnic SNA (SSNA), and renal SNA (RSNA) were recorded before and for 2 hours after lateral cerebroventricular leptin or artificial cerebrospinal fluid administration. Baroreflex function was assessed using a 4-parameter sigmoidal fit of HR and SNA responses to slow ramp (3-5 minutes) changes in MAP, induced by intravenous infusion of nitroprusside and phenylephrine. Leptin (3 μg) increased (P<0.05) basal LSNA, SSNA, RSNA, HR, and MAP, and the LSNA, SSNA, RSNA, and HR baroreflex maxima. Leptin also increased gain of baroreflex control of LSNA and RSNA, but not of SSNA or HR. The elevations in HR were eliminated by pretreatment with methscopalamine, to block parasympathetic nerve activity; however, after cardiac sympathetic blockade with atenolol, leptin still increased basal HR and MAP and the HR baroreflex maximum and minimum. Leptin (1.5 μg) also increased LSNA and enhanced LSNA baroreflex gain and maximum, but did not alter MAP, HR, or the HR baroreflex. Lateral cerebroventricular artificial cerebrospinal fluid had no effects. Finally, to test whether leptin acts in the brain stem, leptin (3 μg) was infused into the 4th ventricle; however, no significant changes were observed. In conclusion, leptin acts in the forebrain to differentially influence baroreflex control of LSNA, RSNA, SSNA, and HR, with the latter action mediated via suppression of parasympathetic nerve activity. (Hypertension. 2013;61:812-819.) • Online Data Supplement Key Words: lumbar sympathetic nerve activity ■ male rats ■ methscopolamine ■ parasympathetic ■ renal sympathetic nerve activity ■ splanchnic sympathetic nerve activity
C linical and experimental studies have shown that obesity is associated with hypertension, attributable at least in part to increases in sympathetic nerve activity (SNA). 1, 2 Considerable effort has been directed toward identifying the underlying mechanisms. As recently reviewed, 2,3 1 potential candidate is leptin, a 16-kDa peptide hormone produced predominantly by white adipocytes. Acute leptin administration increases SNA to multiple organs, including brown adipose tissue, the hindlimb, adrenal gland, and kidney, 3 and chronic leptin infusion produces hypertension. 2, 3 In addition, leptindeficient obese mice (ob/ob mice) fail to exhibit hypertension, despite massive obesity. 2, 3 Another deleterious consequence of obesity is impaired sensitivity of the baroreceptor reflex. [4] [5] [6] Decreased baroreflex function has been identified as a risk factor for subsequent adverse cardiovascular events in humans with type 2 diabetes mellitus. 7 However, the mechanism is unknown. Although leptin has been considered, 8 current information is conflicting. For example, monogenic forms of rodent obesity attributable to loss of leptin or to mutations of the leptin receptor exhibit decreased baroreflex gain (BRG), [9] [10] [11] [12] suggesting that leptin enhances baroreflex function. Conversely, systemic administration of leptin was reported to be ineffective, 13 and microinjection of leptin into the nucleus tractus solitarius (NTS) suppressed baroreflex control of heart rate (HR). 14 Therefore, 1 aim of the present experiments was to further investigate whether leptin influences baroreflex function. Given the well-established sympathoexcitatory effects of leptin, we hypothesized that leptin would also enhance the SNA responses to decreases in arterial pressure (ie, BRG).
A key feature of these experiments is that we compared the effects of leptin on baroreflex control of lumbar SNA (LSNA), renal SNA (RSNA), as well as splanchnic SNA (SSNA). In addition, to test whether leptin influences baroreflex control of HR via changes in the activity of the sympathetic nervous system or the parasympathetic nervous system, experiments were performed to determine whether the effects of leptin on the HR baroreflex were eliminated by systemic pretreatment with drugs that blocked cholinergic (methscopolamine) or β-adrenergic (atenolol) receptors.
Leptin has been shown to increase SNA after selective microinjection into several hypothalamic nuclei [15] [16] [17] [18] [19] and into the NTS. 14, 20 Therefore, to activate these multiple sites concurrently, leptin was infused via a lateral cerebral ventricle (LV). In addition, to begin to identify the sites at which leptin acts to modify baroreflex function, we compared the effects of leptin infusion via the LV, which will activate receptors in both the hypothalamus and NTS, versus the fourth ventricle (4 V), which targets brain stem leptin receptors.
Methods

Animals
Forty male (320-450 g) Sprague-Dawley rats (Charles River Laboratories, Inc) were used for these experiments. All of the rats were acclimated for ≥1 week before experimentation in a room with a 12-hour:12-hour light/dark cycle, with food (LabDiet 5001, Richmond, IN) and water provided ad libitum. All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional (Oregon Health & Science University) Animal Care and Use Committee.
Surgery
Under isoflurane anesthesia, a tracheal tube, femoral arterial and venous catheters, and a recording electrode around the lumbar, splanchnic, or renal sympathetic nerve were implanted (see the online-only Data Supplement for details). After preparing the rat for intracerebroventricular (icv) infusions, a loading dose of α-chloralose (50 mg kg −1 ; Sigma) was administered intravenously over 30 minutes, while isoflurane was slowly withdrawn, and this was followed by a continuous infusion of α-chloralose (25 mg kg −1 h −1 ) for the duration of the experiment. Throughout the experiment, artificial ventilation with 100% oxygen was maintained, and respiratory rate and tidal volume were adjusted to maintain expired CO 2 at 3.5% to 4.5%. Anesthetic depth was regularly confirmed by the lack of a pressor or withdrawal response to a foot or tail pinch. After completion of surgery and the α-chloralose loading dose, rats were allowed to stabilize for ≥60 minutes before experimentation.
Baroreflex Function
Pulsatile and mean arterial pressures (MAPs), HR, and SNA were continuously recorded, and baroreflex function was assessed as previously described 21 (see the online-only Data Supplement for details). Briefly, complete baroreflex curves were constructed by fitting a sigmoidal curve to the changes in HR and SNA induced by slow changes in arterial pressure after intravenous infusion of nitroprusside and phenylephrine. Absolute values of BRG and the mean±SEM of other sigmoidal parameters (baroreflex maxima, minima, and midpoint) are depicted in the figures.
Intracerebroventricular Infusions
With a flat skull and using bregma and the dorsal surface of the dura as zero, single-barreled glass pipettes drawn to a small tip were used for both LV and 4 V infusions. Coordinates for positioning the LV cannulae were as follows (mm from bregma): 1.0 caudal, 1.4 lateral, and 4.2 dorsal. A pipette was placed into the 4 V using the following coordinates (mm): 2.0 caudal to the interaural line, on the midline, and 7.3 ventral to the skull surface. Leptin (R&D Systems) was dissolved in artificial cerebrospinal fluid (CSF) containing (in mmol/L): 128 NaCl, 2.6 KCl, 1.3 CaCl 2 , 0.9 MgCl 2 , 20 NaHCO 3 , 1.3 Na 2 HPO 4 , and 2.0 dextrose, pH 7.4. Correct pipette placement was confirmed at the end of the experiment by infusing ≈100 nL of 2.5% Alcian blue in 0.5 mmol/L per liter of sodium acetate via the same pipette, removing the brain, and verifying the presence of dye in the cerebroventricles.
Experimental Protocols
After stabilization, basal baroreflex function was established by producing ≥2 baroreflex curves, 30 minutes apart, with similar gains; the final control curve was used for data analysis.
Protocol 1
After reestablishment of basal values, LSNA and HR BRG were measured 1 and 2 hours after LV injection of a dose of leptin that has been shown to inhibit food intake when administered in conscious rats 22, 23 (3 μg in 3 μL, followed by 5 μg/h; n=5), a lower leptin dose (1.5 μg in 1.5 μL, followed by 5 μg/h; n=5) or the artificial CSF vehicle (0.6 μL/min; n=5). In separate groups of rats, SSNA (n=6) or RSNA (n=5) and HR BRG were measured after LV injection of the higher leptin dose. The HR and MAP results from the 3 groups of rats receiving the higher leptin dose were combined (n=16).
Protocol 2
After establishing basal baroreflex function, either methscopolamine (1 mg/kg; n=4) or atenolol (2 mg/kgh; n=5) was administered intravenously, at doses previously documented to block cardiac parasympathetic and sympathetic contributions, respectively. 24 Thirty minutes later, baroreflex curves were generated to assess the effects of the blockade alone. Then, leptin was administered icv (3 μg followed by 5 μg/h), and baroreflex function was reassessed after 1 and 2 hours.
Protocol 3
After control measurements, LSNA and HR BRG were measured 1 and 2 hours after leptin (3 μg, followed by 5 μg/h; n=5) administration into the 4 V.
Statistical Analysis
In each protocol, basal data were taken as the average of the 30 second period before each BRG measurement. All data are presented as means±SEM. Between-group differences were evaluated using 1-or 2-way ANOVA for repeated measures and the post hoc Newman-Keuls test. P values <0.05 were considered statistically significant.
Results
LV Leptin Administration Increases Gain of Baroreflex Control of LSNA and RSNA, but Not of SSNA or HR
LV leptin (3 μg) administration increased basal LSNA and RSNA after 1 and 2 hours; the lower dose of leptin (1.5 μg) increased LSNA only at 2 hours (Figures 1 and 2) . In contrast, basal SSNA was not significantly elevated until 2 hours after 3 μg leptin (Figure 2 ). MAP and HR also increased 2 hours after leptin (3 μg) injection; however, 1.5 μg leptin did not significantly alter MAP or HR (Table 1) . Basal values were not significantly changed during icv infusion of artificial CSF ( Figure 1 ; Table 1 ).
Baroreflex control of LSNA, SSNA, RSNA, and HR were differentially altered by icv leptin. Leptin increased LSNA (3 and 1.5 μg doses) and RSNA BRG (Figures 3 and 4) ; the LSNA and RSNA reflex maximum and range were also elevated ( Figures 3 and 4 and Tables S1 and S2 in the online-only Data Supplement; see Figure S1 for representative experiment). On the other hand, whereas the SSNA maximum was elevated 1 and 2 hours after leptin, BRG was not significantly increased ( Figure 4 ; Table S3 ). Similarly, the higher dose of leptin increased the HR reflex maximum and BP 50 after 2 hours (Table S4) , without significantly altering HR BRG ( Figure 5 ). Leptin increased the baroreflex minimum of LSNA and HR (Figures 3 and 5; Tables S1 and S4), but not of RSNA and SSNA (Figure 4 and Tables S2 and S3 ). April 2013
Methscopolamine Blocks the Effect of Leptin to Increase HR and Alter Baroreflex Control of HR
Methscopolamine increased basal HR, without altering MAP; maximum and minimum baroreflex HR were increased, and HR BRG was reduced (Table 2; Figure 6 ). More importantly, after methscopolamine, leptin failed to alter basal MAP, HR, or influence baroreflex control of HR ( Figure 6 ; Table S5 ). To determine whether the failure of leptin to increase HR was a result of a maximal elevation after methscopolamine, the β-agonist isoproterenol (1 μg/kg) was injected intravenously after methscopolamine administration and 2 hours of leptin infusion. Notably, isoproterenol increased HR from 409±19 to 495±23 bpm, a value higher than the baroreflex HR maximum (446±2 bpm; P<0.05; n=3).
Atenolol reduced basal MAP and HR and decreased the baroreflex HR maximum and the HR range ( Figure 6 ; Table 2 ; Table S5 ). After atenolol, 2 hours of leptin infusion increased basal MAP and HR and elevated the baroreflex HR maximum and minimum ( Figure 6 ; Table S5 ). Interestingly, HR gain was reduced 2 hours after initiating the leptin infusion ( Figure 6 ) in atenolol-treated rats.
V Leptin Does Not Alter Basal or Baroreflex Control of LSNA, HR, and MAP
In sharp contrast to the potent effects of leptin administered via the LV, basal MAP, HR, and LSNA, as well as BRG and baroreflex parameters, were not altered during 4 V leptin infusion ( Figure 7 ; Table S6 ).
Discussion
The major goal of this study was to test the hypothesis that leptin acts centrally to enhance baroreflex control of SNA and HR and, if so, to begin to investigate the mechanisms. The important new findings are as follows: (1) leptin increases SSNA (as well as LSNA, RSNA, HR, and MAP, as previously reported 19 ); (2) central leptin exerts differential effects on baroreflex control of LSNA, RSNA, SSNA, and HR; (3) the ability of leptin to increase HR and its baroreflex regulation is eliminated by pretreatment with methscopolamine, to block the parasympathetic nervous system, but not by pretreatment with atenolol, to block cardiac sympathetic effects; and (4) these actions of leptin are not observed when leptin is infused via the 4 V. Collectively, these data indicate that central leptin acts in the forebrain to influence baroreflex control of SNA and HR, with the latter action mediated via suppression of cardiac parasympathetic tone. Previous studies have demonstrated that intravenous or central leptin administration increases LSNA, RSNA, HR, and MAP 19, 25, 26 ; our results confirm this work. A new finding, however, is that leptin also acts centrally to increase SSNA. Dunbar et al 26 reported that icv leptin decreases splanchnic blood flow, which contributes to its pressor effect. The increase in SSNA that we observed suggests that the sympathetic nervous system likely mediates this action. Plasma leptin levels increase after a meal. 27 Therefore, the central action of leptin to increase SSNA may help to maintain arterial pressure at a time when the splanchnic circulation is dilating to accept and distribute absorbed nutrients. In addition, in parallel to the actions of insulin, 28 meal-induced increases in leptin may contribute to enhanced baroreflex control of LSNA.
Monogenetic impairment of the actions of leptin, attributable either to loss of leptin or mutations of the leptin receptor, depresses the baroreflex, [9] [10] [11] [12] suggesting that leptin may support or enhance baroreflex function. However, these rodent models exhibit obesity, and diet-induced obesity also decreases baroreflex control of HR 4, 5, 24 and, in 1 human study, SNA, 29 confounding this suggestion. The present study demonstrates that exogenous leptin administration differentially influences baroreflex function. Increases in BRG were observed for LSNA and RSNA, but not for SSNA or HR. However, leptin increased the baroreflex maximum and range of LSNA, RSNA, SSNA, and HR, as well as the baroreflex minimum of LSNA and HR. Previously, intravenous leptin was shown to increase the range and maximum of baroreflex control of RSNA in mice, without enhancing gain. 13 Different species or routes of leptin administration may explain these divergent results.
The mechanism by which leptin differentially alters baroreflex control of various autonomic efferents was not identified, but may arise from actions of leptin at different brain sites, or within a site on distinct neurons. In support of this supposition, previous studies have demonstrated that leptin acts differentially to increase SNA at several hypothalamic sites containing leptin receptors. 16, 18, 19 We found that leptin increases the baroreflex minimum for LSNA and HR (but not for SSNA or RSNA; see also Reference 13); therefore, leptin can increase LSNA and HR even when baroreflex suppression is maximal at high pressures, suggesting that the neurocircuitry that mediates the increases in LSNA and HR is at least in part independent of, or distal to, brain baroreflex pathways. However, the finding that leptin also increases LSNA BRG suggests an additional interaction with baroreflex pathways. Thus, the brain neurons that initiate the effects of leptin on baroreflex control of different sympathetic nerves may also project to multiple sites in the brain stem and spinal cord.
Obesity mutes leptin's effect to increase SNA to brown adipose tissue and LSNA, yet leptin-induced increases in RSNA are preserved or enhanced. 30, 31 Because leptin increases gain of baroreflex control of LSNA, brain resistance to leptin could explain in part the decrease in muscle SNA BRG reported in obese humans compared with after weight loss. 29 On the other hand, because leptin does not influence SSNA BRG, its loss does not likely contribute to the decreased SSNA gain observed in Zucker rats. 10 Indeed, Schreihofer et al 10 came to the same conclusion, because they found that SSNA BRG is not impaired in juvenile Zucker rats, but only in older Zucker rats that exhibit considerable obesity.
Although the ability of leptin to increase HR has been noted before, 14,18,32 the mechanism has not been directly investigated. Nevertheless, previous work has provided indirect evidence that leptin may suppress parasympathetic control of the heart. First, Arnold et al 14 reported that NTS microinjection of leptin decreased spontaneous baroreflex sensitivity and the reflex bradycardia after bolus intravenous injections of phenylephrine, each of which reflect primarily cardiovagal activity. Second, correlations between leptin and indices of cardiac parasympathetic activity have been noted in humans. 33 Using a pharmacological approach, we directly tested this hypothesis. Administration of methscopolamine to block the parasympathetic nervous system completely prevented the ability of leptin to elevate HR and right-shift the baroreflex curve. This was not attributable to a HR ceiling effect, because after methscopolamine and leptin treatment, intravenous injection of the β-adrenergic agonist, isopreteronol, to mimic cardiac sympathoexcitation, increased HR even higher. Interestingly, methscopolamine also prevented the pressor response to LV leptin. Methscopolamine does not cross the blood-brain barrier, but it can exhibit some cholinergic nicotinic blocking activity. 34 Therefore, 1 explanation for this finding is that methscolpolamine inhibited ganglionic transmission. In support, we have found that intravenous methscopolamine decreases SNA and arterial pressure when administered after leptin infusion (Li et al, unpublished observations). On by guest on May 1, 2016 http://hyper.ahajournals.org/ Downloaded from the other hand, in rats in which cardiac sympathetic activity was blocked with atenolol, leptin increased HR, MAP, and right-shifted the baroreflex curve. Collectively, these data suggest that leptin increases HR at any given MAP by suppressing parasympathetic control of the heart. One of the hallmarks of obesity in humans and experimental animals is suppression of cardiac parasympathetic activity 4, 24, 35 in association with elevated leptin levels. Therefore, we speculate that leptin may contribute to impaired vagal activity during obesity. Interestingly, after atenolol, leptin infusion also markedly decreased BRG. Thus, leptin may also suppress the response of the parasympathetic nervous system to changes in arterial pressure, at least when cardiac sympathetic activity is also reduced. In humans, obesity can reduce sympathetic activity to the heart 1 ; therefore, leptin may also contribute to the impaired cardiac baroreflex sensitivity that is observed.
Leptin has been shown to increase SNA and HR after microinjection into several hypothalamic nuclei (arcuate nucleus, dorsal medial hypothalamus, lateral hypothalamus, and ventromedial hypothalamus) 18, 19, 36 as well as the NTS. 14, 20 However, as we previously found with insulin, 37 leptin infusion into the 4 V, to restrict its actions to the hindbrain, was ineffective. The variance of our study with previous work may be explained by a failure of sufficient leptin to reach its active sites in the NTS, because at least in 1 report, 20 larger doses were used. Regardless of the explanation, our studies show that leptin can act in the forebrain to increase SSNA and influence baroreflex control of LSNA, RSNA, SSNA, and HR. As discussed, in view of the variable effects on baroreflex control of SNA and HR that were observed, >1 site may be involved.
Although the results of this study clearly demonstrate a differential effect of leptin on baroreflex function, there are several limitations that must be considered. First, the experiments were performed in anesthetized rats. Although we acknowledge that it will be important to repeat these experiments in conscious animals, it is noteworthy that α-chloralose was chosen as the anesthetic, because baroreflex function is relatively preserved. Indeed, the values of LSNA BRG measured in the present study are essentially identical to values obtained in conscious rats. 38, 39 Second, the concentrations of leptin achieved in the CSF were certainly supraphysiological. However, high doses are required to establish a significant diffusion gradient, because as a large peptide only limited amounts of leptin penetrate brain from the CSF and only very slowly. 40 The fact that the stimulatory effects of leptin on LSNA in the present study were related more to the initial bolus dose than to the total infused amount supports this contention. Importantly, in rats, intravenous infusion of doses that increase plasma leptin within the physiological-pathophysiological range increase SNA similarly to the present study, 25 strongly suggesting that such levels of plasma leptin would also enhance baroreflex control. Third, the short-term effects of leptin that we observed may underestimate the potency of long-term elevations. In support, in agreement with previous work, 16, 25 we found that the SNA responses to LV leptin are slowly developing and may not have peaked within our 2-hour study period. Moreover, chronic intracerebroventricular infusion of significantly lower doses of leptin are sufficient to elevate arterial pressure and suppress food intake. 41 
Perspectives
In both humans and animals, elevations in plasma leptin occur soon after beginning a high-fat diet and accruing excess adiposity, in association with activation of the sympathetic nervous system. [42] [43] [44] Thus, the hypothesis that increased leptin contributes to obesity-induced sympathoexcitation has received considerable attention. 2, 3 Another hallmark of obesity is depressed basal parasympathetic nerve activity and impaired HR baroreflex function, which also rapidly develops. [4] [5] [6] 24, 35, 44 The present results suggest that leptin may also contribute to these cardiovascular consequences. On the other hand, in obese humans, baroreflex control of muscle SNA has been reported to be depressed 29, 45 or preserved. 46, 47 Therefore, if leptin is involved in SNA baroreflex impairment, then the factor(s) that reduce brain sensitivity to leptin's action to enhance BRG must vary among individuals. Future experiments are required to identify the factors that modify sensitivity of the brain to leptin and to determine whether and how the impact of these factors varies among obese individuals.
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What Is New?
• Leptin acts in the brain to increase splanchnic sympathetic nerve activity (SSNA).
• Leptin increases lumbar SNA and renal SNA baroreflex gain (but not gain of baroreflex control of SSNA or heart rate) and increases lumbar SNA, SSNA, renal SNA, and heart rate baroreflex maxima and range.
• Leptin increases heart rate via suppression of parasympathetic nerve activity.
• Leptin exerts these effects via an action in the forebrain.
What Is Relevant?
• Obesity increases leptin. Therefore, leptin may contribute to the suppression of basal and baroreflex-mediated changes in parasympathetic nerve activity commonly observed in obese individuals and identified as a risk factor for adverse cardiovascular events.
• After a meal, like insulin, increases in leptin may contribute to enhanced lumbar SNA baroreflex gain and may counteract splanchnic vasodilation via increases in SSNA.
Summary
Leptin acts in the forebrain to differentially influence baroreflex control of lumbar SNA, SSNA, renal SNA, and heart rate, with the latter action mediated via suppression of parasympathetic nerve activity.
Methodological details.
Surgery. Anesthesia was induced with 5% isoflurane (Novaplus) in 100% oxygen and was maintained with 1.5-2% isoflurane. Throughout the surgery and experimental protocol, body temperature was maintained at 37±1 • C using a rectal thermistor and heating pad. A tracheal tube was placed for artificial ventilation, and femoral arterial (1) and venous (3) catheters were implanted for the measurement of mean arterial pressure (MAP) and drug infusions, respectively. After a midline abdominal incision, the lumbar nerve was carefully dissected free of the surrounding tissue, and a bipolar stainless steel electrode was positioned and secured around it using lightweight silicone material (Kwik-Sil, WPI, Inc., Sarasota, FL,USA). In separate groups of rats, the renal or post-celiac segment of the splanchnic nerve was exposed through a flank incision and retroperitoneal approach and a recording electrode was secured as for the lumbar nerve. Rats were then placed in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA). For LV injections, a small hole was burred through the skull on the midline just caudal to bregma. Data acquisition. Pulsatile and mean arterial pressures, HR and SNA were continuously recorded on a Grass polygraph by connecting the arterial catheter to a Grass bridge amplifier. The pulsatile signal was directed to a Grass tachograph amplifier for determination of HR. Arterial pressure, HR and SNA were continuously recorded using a Biopac MP100 data acquisition and analysis system sampling at 2000
Hz. SNA was band-pass filtered (100-3000 Hz), amplified (×10,000), rectified and integrated in 1 s bins. MAP and HR data were also grouped into 1 s bins from which mean values were obtained. Post-mortem SNA was quantified at the end of the experiment, and this background level was subtracted from values of SNA recorded during the experiment. SNA was normalized to control SNA before the experimental infusions were initiated (% of control).
Baroreflex function. Pulsatile and mean arterial pressures, HR and SNA were continuously recorded, and baroreflex function was assessed as previously described (see Supplement for details).Complete sigmoidal baroreflex curves were generated by first quickly lowering MAP to ∼50 mmHg by intravenous infusion of nitroprusside (1 mg ml −1 ; 20μl min −1 ), and then by steadily and smoothly raising MAP to ∼175 mmHg over 3- 
